Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
BLUE Analyst Ratings
Hold
1 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BLUE Stock 12 Month Forecast
Average Price Target
$6.00
▲(16.50% Upside)
| Highest Price Target$8.00 | Average Price Target$6.00 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Barclays
Reiterated
03/28/25
Robert W. Baird
Downgraded
02/24/25
William Blair
Reiterated
02/21/25
Wells Fargo
Reiterated
02/21/25
RBC Capital
$80→$8
Hold
55.34%
Upside
Reiterated
01/07/25
Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'
Leerink Partners
$1→$10
Hold
94.17%
Upside
Reiterated
01/03/25
Analysts Offer Insights on Healthcare Companies: Cencora (NYSE: COR) and Bluebird Bio (NASDAQ: BLUE)
Bank of America Securities
$60→$10
Hold
94.17%
Upside
Downgraded
11/15/24
Bluebird Bio downgraded to Neutral from Buy at BofABluebird Bio downgraded to Neutral from Buy at BofA
Oppenheimer
―
Hold
―
Reiterated
08/15/24
Oppenheimer reiterates Perform Rating on bluebird bio (BLUE)Oppenheimer analyst Mark Breidenbach reiterated a Perform rating on bluebird bio (NASDAQ: BLUE).
Goldman Sachs
$20
Sell
288.35%
Upside
Reiterated
05/09/24
We note that BLUE expects gross-to-net discounts of 20% to 25% across all three therapies in 2024. On Zynteglo, 31 total patients have undergone cell collection to date (20 collections occurred in 2023 and 11 collections have occurred in 2024). On Skysona, nine patients have undergone cell collections to date (six patients underwent cell collection in 2023 and three have taken place in 2024). On Lyfgenia in sickle cell disease (SCD; approved in December 2023), BLUE recently announced the first patient start. Management reiterated guidance of 85 to 105 patient starts in 2024 across its three therapies. Management continues to report patient starts (defined by the time when cell collection occurs - noting that revenue is recognized upon infusion of the gene therapy into the patient) as the key Salveen Richter, CFA | Goldman Sachs & Co.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Barclays
Reiterated
03/28/25
Robert W. Baird
Downgraded
02/24/25
William Blair
Reiterated
02/21/25
Wells Fargo
Reiterated
02/21/25
RBC Capital
$80→$8
Hold
55.34%
Upside
Reiterated
01/07/25
Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'
Leerink Partners
$1→$10
Hold
94.17%
Upside
Reiterated
01/03/25
Analysts Offer Insights on Healthcare Companies: Cencora (NYSE: COR) and Bluebird Bio (NASDAQ: BLUE)
Bank of America Securities
$60→$10
Hold
94.17%
Upside
Downgraded
11/15/24
Bluebird Bio downgraded to Neutral from Buy at BofABluebird Bio downgraded to Neutral from Buy at BofA
Oppenheimer
―
Hold
―
Reiterated
08/15/24
Oppenheimer reiterates Perform Rating on bluebird bio (BLUE)Oppenheimer analyst Mark Breidenbach reiterated a Perform rating on bluebird bio (NASDAQ: BLUE).
Goldman Sachs
$20
Sell
288.35%
Upside
Reiterated
05/09/24
We note that BLUE expects gross-to-net discounts of 20% to 25% across all three therapies in 2024. On Zynteglo, 31 total patients have undergone cell collection to date (20 collections occurred in 2023 and 11 collections have occurred in 2024). On Skysona, nine patients have undergone cell collections to date (six patients underwent cell collection in 2023 and three have taken place in 2024). On Lyfgenia in sickle cell disease (SCD; approved in December 2023), BLUE recently announced the first patient start. Management reiterated guidance of 85 to 105 patient starts in 2024 across its three therapies. Management continues to report patient starts (defined by the time when cell collection occurs - noting that revenue is recognized upon infusion of the gene therapy into the patient) as the key Salveen Richter, CFA | Goldman Sachs & Co.
Best Analysts Covering Bluebird Bio
Which Analyst Should I Follow If I Want to Buy BLUE and Sell After:
1 Month
xxx
Success Rate
10/24 ratings generated profit
Average Return
+0.27%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 41.67% of your transactions generating a profit, with an average return of +0.27% per trade.
3 Months
xxx
Success Rate
15/24 ratings generated profit
Average Return
+6.61%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +6.61% per trade.
1 Year
2 Years
xxx
Success Rate
11/24 ratings generated profit
Average Return
+50.42%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 45.83% of your transactions generating a profit, with an average return of +50.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BLUE Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Jan 25
Feb 25
Mar 25
Strong Buy
6
5
4
3
2
Buy
0
0
0
0
0
Hold
12
9
8
11
7
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
18
15
13
15
9
Each month's total comprises the sum of three months' worth of ratings.
BLUE Financial Forecast
BLUE Stock Forecast FAQ
What is BLUE’s average 12-month price target, according to analysts?
Based on analyst ratings, bluebird bio’s 12-month average price target is $6.00.
What is BLUE’s upside potential, based on the analysts’ average price target?
bluebird bio has 16.50% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BLUE a Buy, Sell or Hold?
bluebird bio has a consensus rating of Hold which is based on 1 buy ratings, 3 hold ratings and 0 sell ratings.
What is bluebird bio’s price target?
The average price target for bluebird bio is $6.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $5.00. The average price target represents 16.50% Increase from the current price of $5.15.
The highest analyst price target is $8.00 ,the lowest forecast is $5.00. The average price target represents 16.50% Increase from the current price of $5.15.
What do analysts say about bluebird bio?
bluebird bio’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of BLUE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.